InVitae Corp (NVTA)

NYSE
27.74
+1.65(+6.32%)
After Hours
28.00
+0.26(+0.94%)
- Real-time Data
  • Volume:
    4,167,363
  • Bid/Ask:
    27.63/28.10
  • Day's Range:
    26.28 - 28.16

NVTA Overview

Prev. Close
26.09
Day's Range
26.28 - 28.16
Revenue
318.97M
Open
26.28
52 wk Range
15.22 - 61.58
EPS
-3.93
Volume
4,167,363
Market Cap
5.82B
Dividend (Yield)
N/A (N/A)
Average Vol. (3m)
4,507,186
P/E Ratio
-
Beta
1.95
1-Year Change
78.16%
Shares Outstanding
209,683,161
Next Earnings Date
Aug 10, 2021
What is your sentiment on InVitae Corp?
or
Market is currently closed. Voting is open during market hours.

InVitae Corp News

InVitae Corp Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellSellSellNeutral
Technical IndicatorsStrong SellSellStrong BuyStrong SellStrong Sell
SummaryStrong SellSellNeutralStrong SellSell

InVitae Corp Company Profile

InVitae Corp Company Profile

Employees
2100

Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. As of December 31, 2016, the Company's products consisted of assays totaling over 1,100 genes that could be used for multiple indications, including hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders and other hereditary conditions. The Company offers panels for a range of hereditary conditions in cancer, cardiology, neuromuscular, pediatric and rare diseases. The Company focuses on genetic testing, genome network and genome management. The Company offers full gene sequencing and deletion/duplication analysis as a standard for all of its tests. The Company holds interests in AltaVoice, a patient-centered data company.

Read More
  • good stock, load more!
    1
    • 7.43 a year a go..P/E Ratio N/A
      2
      • The Cathie Wood effect. A +6% to any stock.
        0
        • being following since 2015. So much hype. They keep adding the competition and more losses on their balance sheets, with hope that sometime in the future everyone will want to do DNA tests, for everything. Apparently, privacy will be of no concern.
          0
        • I would gladly do cheap DNA tests twice a year at the doctor to scan for possible risks in my genes. Or a bloodtest to check for cancer particles. All of this will for sure happen in the near future.
          0
        • this goes to zero by the time that happens. so much lossess, so much dilluation of shares, when FED closes the money gates, this is a dead investment, you will lose money
          0
      • Motley Stock advisor pick. I'm in for the long
        1
        • https://finance.yahoo.com/news/palantir-replaces-gamestop-wallstreetbets-top-084327519.html
          0
          • Earnings to be announced tomorrow after close
            0
            • up and down, up and down.... why?
              0
              • maybe uncertainty or his report, don't u think?
                0
              • doing this for a long time. So i don t belivr its thst
                0
            • Does anyone know what is happening to this stock. Any sensible insight appreciated
              0
              • Weird that this is down today
                0
                • New Trend for Medical and also new trends for the world.
                  0
                  • Stock is correcting due to financials. ROCE is (-). Means the company is blowing money and inefficient. EPS will be lower unless they change.
                    5
                    • BS ! Normal process to raise funding to expand. I am In since yesterday
                      0
                  • Finally I am in!
                    0
                    • mm this one is on the verge of going lower or resume the positive path
                      0
                    • How do i get in pls
                      0
                  • Cheap nvta? Yes plz may i have some more
                    0
                    • EASY BUY @46.88
                      1
                      • Now is at 41
                        0
                    • Why going down? Any news?
                      0
                      • nope
                        0
                    • Invitae will shock the world on Feb. 15
                      0
                      • why ?
                        0
                    • Invitae will shock the world on Feb. 15
                      0
                      • Waiting
                        0
                    • Cocrystal Pharma, Inc. (COCP), +20%
                      0
                      • Iin3rd quarter earning coming up
                        0
                        • im thinking of doing in and outs with that stock. any recommendation?
                          0
                          • very risky not playing long with this type of stock, one news can give them +20% and one can give them -15%... and now all the market is influencing the behaviour
                            0
                          • Strong fundamentals and top stock in ARKG. I would go for the long way
                            0
                          • thank you guys
                            0
                        • Its been very good to me. Up 45% in 7 months.
                          0
                          • what is the the limit
                            0
                            • Their strategy is very simply: buy, acquire, buy, acquire ...
                              0
                              • Gonna crash hard after earnings.
                                4
                                • Too expensive...short term
                                  1
                                  • Cathie Woods is a genius i wouldnt bet against her....
                                    1
                                Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.